Skip to main content
ALMS
NASDAQ Life Sciences

Director Akkaraju Srinivas Makes Nearly $10M Open Market Purchase in ALMS

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$22.56
Mkt Cap
$2.757B
52W Low
$2.76
52W High
$23
52W Position info
717% above low
Off High info
1.9% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

ALMS has more than doubled off its 52-week low of $2.76 on elevated volume (1.9× avg).

Summary

A director of Alumis Inc. made a substantial open market purchase of the company's common stock, signaling strong confidence.


Key Events · Ownership and Investor Activity · ALMS

  • Significant Insider Purchase

    Director Akkaraju Srinivas, through Samsara Opportunity Fund, L.P., purchased 588,235 shares of Alumis Inc. common stock for a total value of $9,999,995.

  • Strong Vote of Confidence

    This substantial open market transaction by a director signals strong conviction in the company's valuation and future performance.

  • Purchase Price Context

    The shares were acquired at $17.00 each on January 9, 2026, which is below the current trading price of $22.56.


Analysis · ALMS · Life Sciences

Srinivas Akkaraju, a director of Alumis Inc., executed a significant open market purchase of nearly $10 million worth of common stock through Samsara Opportunity Fund, L.P. This substantial investment by an insider, particularly a director, indicates strong conviction in the company's future prospects. The purchase was made at $17.00 per share on January 9, 2026, which is below the current stock price of $22.56. Such a large insider buy can be a positive signal to the market, implying that those closest to the company believe the stock has significant upside potential.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALMS was trading at $22.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $2.76 to $23.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALMS - Latest Insights

ALMS
Sep 09, 2026, 9:39 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $9.82
Real-time Price: $10.08 info
Change: +$0.260 (+3%) info
Market Cap: $1.322B info
ALMS
Sep 01, 2026, 10:56 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $9.04
Real-time Price: $10.08 info
Change: +$1.04 (+12%) info
Market Cap: $1.322B info
ALMS
Sep 01, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.80
Real-time Price: $10.08 info
Change: -$12.72 (-56%) info
Market Cap: $1.322B info
ALMS
Sep 01, 2026, 7:34 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $22.80
Real-time Price: $10.08 info
Change: -$12.72 (-56%) info
Market Cap: $1.322B info
ALMS
Aug 17, 2026, 6:09 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $25.30
Real-time Price: $10.08 info
Change: -$15.22 (-60%) info
Market Cap: $1.322B info